Anticoagulants remain the primary strategy for the prevention and treatment of thrombosis.
Unfractionated heparin, low molecular weight heparin, fondaparinux, and warfarin have …

Therapeutic options for the management of venous thromboembolism (VTE) in patients with
cancer remain very limited. Although low-molecular-weight heparin monotherapy has been …

Background Current clinical practice guidelines all recommend the use of therapeutic doses
of low molecular weight heparins (LMWH) for the initial and long-term treatment of cancer …

Acute pulmonary embolism (PE) poses a significant burden on health and survival. Its
severity ranges from asymptomatic, incidentally discovered subsegmental thrombi to …

Background: New oral anticoagulants (NOACs), including direct thrombin inhibitors (DTIs)
and factor Xa (FXa) inhibitors, are emerging alternatives for prophylaxis and treatment of …

Background Venous thromboembolism occurs commonly in patients with cancer. Direct oral
anticoagulants are non-inferior to conventional anticoagulants for the treatment of venous …

A classic text since it was first published in 1974, the Lippincott Manual for Nursing Practice
(LMNP) has provided essential nursing knowledge and up-to-date information on patient …

Essentials• We investigated direct oral anticoagulant (DOAC) use in venous
thromboembolism and thrombophilia.• A comprehensive search identified 10 studies, 8 of …

Background: Apixaban and rivaroxaban are replacing vitamin K antagonists for the
treatment of venous thromboembolism (VTE) in adults; however, head-to-head comparisons …

Objective Doses of 10 mg, 15 mg, and 20 mg of rivaroxaban are approved for the treatment
and prevention of thromboembolic disorders in adult patients. In six Phase I studies, the …